SCHEMBL5214510

SCHEMBL5214510

O=C(O)N1CCN(c2ccc(OCc3ccccc3)cn2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 5/20 0.57
ME1 P48163 5/20 0.57
ME3 Q16798 5/20 0.57
SLC6A7 Q99884 1/20 0.57
GPR119 Q8TDV5 1/20 0.55
P4HTM Q9NXG6 1/20 0.53
MAPT P10636 5/20 0.50
HTT P42858 4/20 0.50
ALDH1A1 P00352 4/20 0.50
RAB9A P51151 2/20 0.50
NPC1 O15118 1/20 0.50
HDAC1 Q13547 1/20 0.48
LMNA P02545 3/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
MAPK1 P28482 1/20 0.48
CYP2C19 P33261 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KDM4E B2RXH2 3/20 0.46
TSHR P16473 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12458573 0.88 ME2 (0.59) ME2ME1ME3SLC6A7GPR119
SCHEMBL23259338 0.88 ME2 (0.59) ME2ME1ME3SLC6A7GPR119
SCHEMBL21551042 0.87 SLC6A7 (0.62) SLC6A7GPR119P4HTMMAPTKDM4E
SCHEMBL30931813 0.85 GPR119 (0.76) ME2ME1ME3SLC6A7GPR119
SCHEMBL3802326 0.85 ME2 (0.56) ME2ME1ME3SLC6A7GPR119
SCHEMBL23259131 0.85 ME2 (0.59) ME2ME1ME3SLC6A7GPR119
SCHEMBL1103897 0.85 GPR119 (0.76) ME2ME1ME3SLC6A7GPR119
Acetic Acid SCHEMBL27439012 0.85 P4HTM (0.53) ME2ME1ME3SLC6A7GPR119
SCHEMBL2357897 0.84 ME2 (0.55) ME2ME1ME3SLC6A7GPR119
SCHEMBL21551627 0.82 SLC6A7 (0.58) SLC6A7GPR119P4HTMMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 EP disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 US disclosed
US-20220315556-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-10-06 US disclosed
EP-3790871-A1 FURIN INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2021-03-17 EP disclosed
WO-2019215341-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-11-14 WO disclosed
EP-1373220-B1 BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION ABBOTT LAB (US) 2007-05-30 EP disclosed
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315556-A1 FURIN INHIBITORS FURIN, TGFB1, PCSK7 ME2 2267/4885ME1 1435/4885ME3 2820/4885
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction CYP19A1, SHBG, CYP17A1 ME2 355/4885ME1 1013/4885ME3 252/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 ME2 2267/4885ME1 1435/4885ME3 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.